Evidence map›Paper›PMID 20433742›Full record

ArticleMolecular cancer2010

Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.

Bo Song, Yuan Wang, Matthew A Titmus, Galina Botchkina, Andrea Formentini, Marko Kornmann, Jingfang Ju

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 3 pooled it
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 3 syntheses or guidelines pooled it, 264 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
  18. Review
  19. Review
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Bo SongTranslational Research Laboratory, Department of Pathology, School of Medicine, Stony Brook University, Stony Brook, New York 11794, USA.
Yuan Wang
Matthew A Titmus
Galina Botchkina
Andrea Formentini
Marko Kornmann
Jingfang Ju
Stony Brook University · USUniversität Ulm · DEWuhan University · CN

Funding

Modulation of Serotonergic TransportersR01MH075020 · NIMH · GEORGETOWN UNIVERSITY · PI SIDHU, ANITA · 2007 to 2010
$1.3M
Novel Method for Isolating Actively Translated mRNAsR21CA114043 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI JU, JINGFANG · 2006 to 2007
$259k
NCI NIH HHS CA114043NIMH NIH HHS MH075020
6 · The paper itself

Abstract

backgroundTranslational control mediated by non-coding microRNAs (miRNAs) plays a key role in the mechanism of cellular resistance to anti-cancer drug treatment. Dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS, TS) are two of the most important targets for antifolate- and fluoropyrimidine-based chemotherapies in the past 50 years. In this study, we investigated the roles of miR-215 in the chemoresistance to DHFR inhibitor methotrexate (MTX) and TS inhibitor Tomudex (TDX).

resultsThe protein levels of both DHFR and TS were suppressed by miR-215 without the alteration of the target mRNA transcript levels. Interestingly, despite the down-regulation of DHFR and TS proteins, ectopic expression of miR-215 resulted in a decreased sensitivity to MTX and TDX. Paradoxically, gene-specific small-interfering RNAs (siRNAs) against DHFR or TS had the opposite effect, increasing sensitivity to MTX and TDX. Further studies revealed that over-expression of miR-215 inhibited cell proliferation and triggered cell cycle arrest at G2 phase, and that this effect was accompanied by a p53-dependent up-regulation of p21. The inhibitory effect on cell proliferation was more pronounced in cell lines containing wild-type p53, but was not seen in cells transfected with siRNAs against DHFR or TS. Moreover, denticleless protein homolog (DTL), a cell cycle-regulated nuclear and centrosome protein, was confirmed to be one of the critical targets of miR-215, and knock-down of DTL by siRNA resulted in enhanced G2-arrest, p53 and p21 induction, and reduced cell proliferation. Additionally, cells subjected to siRNA against DTL exhibited increased chemoresistance to MTX and TDX. Endogenous miR-215 was elevated about 3-fold in CD133+HI/CD44+HI colon cancer stem cells that exhibit slow proliferating rate and chemoresistance compared to control bulk CD133+/CD44+ colon cancer cells.

conclusionsTaken together, our results indicate that miR-215, through the suppression of DTL expression, induces a decreased cell proliferation by causing G2-arrest, thereby leading to an increase in chemoresistance to MTX and TDX. The findings of this study suggest that miR-215 may play a significant role in the mechanism of tumor chemoresistance and it may have a unique potential as a novel biomarker candidate.

Indexed as

Gene Expression RegulationAdultAgedAged, 80 and overAntineoplastic AgentsBlotting, WesternCell Line, TumorCell ProliferationColonic NeoplasmsDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesHumansMaleMethotrexateMicroRNAsAntineoplastic AgentsDTL protein, humanMethotrexateMicroRNAsNuclear ProteinsQuinazolinesraltitrexedRNA, Small InterferingTetrahydrofolate DehydrogenaseThiophenesThymidylate SynthaseUbiquitin-Protein Ligases

Identifiers

PMID20433742
PMCPMC2881118
OpenAlexW2149954427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.